GeoVax Labs, Inc. New
GOVXGeoVax Labs, Inc. is a biotechnology company focused on developing innovative vaccines and immunotherapies for infectious diseases and cancers. The company leverages its proprietary MVA-VLP (Modified Vaccinia Ankara-Virus-Like Particle) platform to create candidates aimed at HIV, Ebola, Zika, and COVID-19, among others. GeoVax aims to advance its vaccine candidates through clinical trials to address unmet medical needs globally.
Company News
Several biotech companies are advancing cancer research with promising clinical milestones, focusing on innovative immunotherapies and targeted treatments amid rising cancer incidence and potential research funding challenges.
EmergingGrowth.com announced the schedule for its 84th conference featuring presentations from multiple public companies across technology, biotech, and other sectors on July 16-17, 2025.
EmergingGrowth.com announces the schedule for the 78th Emerging Growth Conference, featuring presentations from various companies across different growth sectors.
GeoVax Labs, a biotechnology company, announced that its CEO will present at the NobleCon20 conference. The company is developing COVID-19 vaccines and cancer immunotherapies, with its lead clinical programs being GEO-CM04S1 and Gedeptin.
GeoVax Labs announced progress in its COVID-19 vaccine trials, including the BARDA/Project NextGen Phase 2b trial and upcoming data readouts from existing Phase 2 trials. The company also provided updates on its Gedeptin and GEO-MVA Mpox vaccine programs.
